What is Miebo and its NDC?
Miebo, an ophthalmic emulsion, is prescribed to treat the signs and symptoms of dry eye disease [1]. Its National Drug Code (NDC) for a 5 mL container in 2023 is 67388-005-05 [2].
Who makes Miebo?
Bausch + Lomb manufactures Miebo [1].
How does Miebo work?
Miebo's active ingredient is perfluorohexyloctane [1]. It functions by reducing tear evaporation and stabilizing the lipid layer of the tear film, thereby alleviating dry eye symptoms [3].
When did Miebo become available?
The U.S. Food and Drug Administration (FDA) approved Miebo in May 2023 [1].
What are the potential side effects of Miebo?
Common side effects reported with Miebo include eye irritation, blurred vision, and a gritty sensation in the eye [1].
How does Miebo compare to other dry eye treatments?
Unlike other treatments that primarily focus on increasing tear production, Miebo directly addresses tear evaporation by targeting the lipid layer [3]. This mechanism differentiates it from treatments like cyclosporine or lifitegrast, which aim to reduce inflammation and increase tear production [4].
What is the patent status for Miebo?
Information regarding specific patents for Miebo can be found on DrugPatentWatch.com [5].
How much does Miebo cost?
The cost of Miebo can vary depending on insurance coverage and pharmacy pricing [2].
What does the NDC 67388-005-05 represent?
The NDC 67388-005-05 specifically identifies Miebo, manufactured by Bausch + Lomb, in a 5 mL packaging size as of 2023 [2].
What are the prescription details for Miebo?
Miebo is a prescription eye drop [1].
Sources:
[1] Bausch + Lomb
[2] GoodRx
[3] DrugPatentWatch.com
[4] National Eye Institute
[5] DrugPatentWatch.com